Stockscreener 앱 받기
14.50
3.27%
-0.49
시간 외 거래:
14.50
전일 마감가:
$14.99
열려 있는:
$15
하루 거래량:
846.20K
Relative Volume:
0.50
시가총액:
$794.25M
수익:
$15.84M
순이익/손실:
$-308.48M
주가수익비율:
-2.2377
EPS:
-6.48
순현금흐름:
$-153.08M
1주 성능:
-0.34%
1개월 성능:
+2.04%
6개월 성능:
-2.75%
1년 성능:
+87.34%
1일 변동 폭
$14.32
$15.01
1주일 범위
$13.55
$15.84
52주 변동 폭
$4.45
$19.18
Uniqure N V Stock (QURE) Company Profile
명칭
Uniqure N V
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
QURE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
14.50 | 796.59M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-01 | 재개 | Chardan Capital Markets | Buy |
| 2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-09 | 개시 | Jefferies | Buy |
| 2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-08-25 | 개시 | Raymond James | Strong Buy |
| 2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 개시 | Cowen | Outperform |
| 2019-12-03 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Outperform |
| 2019-10-11 | 개시 | Stifel | Buy |
| 2019-09-25 | 개시 | Bernstein | Outperform |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure N V 주식(QURE)의 최신 뉴스
uniQure N.V. Stock Analysis and ForecastFree Real-Time Stock Data - Autocar Professional
What drives uniQure N.V. stock priceFree Stock Chart Pattern Guide - Autocar Professional
What analysts say about uniQure N.V. stockHigh-yield market plays - Autocar Professional
Is uniQure N.V. a good long term investmentDynamic profit opportunities - jammulinksnews.com
Why uniQure N.V. stock attracts strong analyst attentionReal Chart Play - Newser
What makes uniQure N.V. stock price move sharplyHigh Reward Swing Trades - Newser
(QURE) Trading Advice - news.stocktradersdaily.com
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
uniQure N.V. (NASDAQ:QURE) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
(QURE) Technical Data - news.stocktradersdaily.com
uniQure stock rating reiterated at Buy by Stifel ahead of key data - Investing.com
Is uniQure NV overvalued or undervalued? - MarketsMojo
uniQure N.V. director Balachandran Madhavan sells $30,518 in shares - Investing.com
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint - Yahoo Finance
11 Best Genomics Stocks to Buy According to Hedge Funds - Insider Monkey
uniQure N.V. chief legal officer Potts sells $70k in shares By Investing.com - Investing.com South Africa
uniQure: Price And Value Have Caught Up (NASDAQ:QURE) - Seeking Alpha
Assenagon Asset Management S.A. Acquires 261,323 Shares of uniQure (NASDAQ:QURE) - Defense World
uniQure (NASDAQ:QURE) Stock Rating Lowered by Wall Street Zen - Defense World
uniQure shareholders approve executive compensation, board reappointments By Investing.com - Investing.com South Africa
uniQure shareholders approve executive compensation, board reappointments - Investing.com
uniQure (QURE) Appoints Kylie O'Keefe to Advance Global Strategy - GuruFocus
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer By Investing.com - Investing.com South Africa
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer - Investing.com India
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer - GlobeNewswire
uniQure Prepares for Historic Huntington's Disease Treatment Launch with Key Executive Hire - Stock Titan
Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com
uniQure (QURE) Positioned for Growth Amid Regulatory Changes - GuruFocus
RFK Jr. looks to fast track rare disease drug approvals (updated) - Seeking Alpha
Bank of America Corp DE Has $1.22 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World
Stock Traders Buy Large Volume of uniQure Call Options (NASDAQ:QURE) - Defense World
stifel reiterates buy rating on uniQure stock after CEO meeting By Investing.com - Investing.com UK
uniQure (NASDAQ:QURE) Short Interest Update - Defense World
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting By Investing.com - Investing.com South Africa
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting - Investing.com Australia
uniQure aligns with FDA on Huntington’s therapy path By Investing.com - Investing.com South Africa
uniQure provides regulatory update on AMT-130 for Huntington’s Disease - TipRanks
UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy - marketscreener.com
Transcript : UniQure N.V.Special Call - marketscreener.com
UniQure Provides Regulatory Update On Amt-130 For Huntington'S Disease - marketscreener.com
Uniqure N V (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):